Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (PAVM) is a commercial-stage medical technology leader driving innovation in diagnostic testing, medical devices, and digital health solutions. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, clinical milestones, and strategic initiatives shaping the future of preventive care technologies.
Access official press releases, earnings reports, and regulatory filings in one centralized location. Our curated collection features updates on product commercialization progress, FDA clearances, and partnership announcements, enabling stakeholders to track the company’s execution of its rapid concept-to-market strategy across multiple healthcare sectors.
Key content categories include financial performance updates, new product launches, clinical study results, and executive leadership developments. The resource is particularly valuable for monitoring advancements in PAVmed’s flagship diagnostic tools like the EsoGuard test and digital health platforms through subsidiary Veris Health.
Bookmark this page for streamlined access to verified information directly from corporate communications. Check regularly for updates on PAVmed’s progress in commercializing technologies designed to improve early disease detection and patient care delivery.
Lucid Diagnostics (LUCD) announced that the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines has updated its recommendations to include esophageal precancer screening. The new guidelines now reference professional society guidelines that recommend non-endoscopic biomarker testing, such as Lucid's EsoGuard® Esophageal DNA Test with EsoCheck® Collection Device, as an acceptable alternative to invasive upper endoscopy for detecting esophageal precancer (Barrett's Esophagus).
This update aligns with the American College of Gastroenterology (ACG) Clinical Guideline and represents a significant step toward recognizing esophageal precancer testing's role in cancer prevention. The company expects this alignment between NCCN Guidelines and gastroenterology society guidelines to positively influence commercial insurance coverage decisions and expand access to EsoGuard testing.
Lucid Diagnostics (Nasdaq: LUCD) announced the acceptance of its ENVET-BE clinical utility study for publication in Gastroenterology & Hepatology, marking the fifth peer-reviewed publication supporting its EsoGuard® Esophageal DNA Test.
The study, examining data from 199 EsoGuard-positive patients who underwent confirmatory upper endoscopy (EGD), demonstrated that EsoGuard significantly improves the detection of esophageal precancer (Barrett's Esophagus or BE). Key findings show:
- 2.4-fold higher diagnostic yield for BE compared to screening EGD alone
- Nearly three-fold higher yield in patients meeting American College of Gastroenterology screening criteria
This research validates EsoGuard as an effective non-invasive triage tool, allowing most at-risk patients to avoid invasive procedures while enhancing the efficiency of endoscopy resource utilization. The study supports ongoing efforts to secure positive commercial insurance coverage policies, following recent success with Highmark Blue Cross Blue Shield.
Lucid Diagnostics (LUCD) has achieved a significant milestone with its first positive commercial insurance coverage for the EsoGuard® Esophageal DNA Test through Highmark Blue Cross Blue Shield in New York state. The regional BCBS plan will cover non-invasive screening of esophageal precancer and cancer for patients meeting established professional society guidelines for testing.
This landmark coverage decision is expected to serve as a precedent for other commercial insurers to follow suit. According to Dr. Lishan Aklog, Lucid's Chairman and CEO, this development validates their clinical evidence base. The company continues to engage with commercial insurers nationwide to expand access to EsoGuard precancer testing.
PAVmed (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for March 25, 2025, at 8:30 AM ET.
During the call, Chairman and CEO Lishan Aklog, M.D., will provide a business update and overview of company operations and growth strategy. President and CFO Dennis McGrath will discuss fourth quarter 2024 financial results.
- U.S. callers can dial 1-800-836-8184
- International callers can dial 1-646-357-8785
- Conference name: 'PAVmed Business Update'
A 30-day replay will be available in the investor relations section at pavmed.com following the call.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has scheduled a business update conference call and webcast for March 24, 2025, at 8:30 AM ET.
During the call, Chairman and CEO Lishan Aklog will provide a comprehensive business update, including the company's operations and growth strategy. CFO Dennis McGrath will present the fourth quarter 2024 financial results.
Investors can access the webcast through the company's investor relations website at luciddx.com. For telephone access:
- U.S. callers: 1-800-836-8184
- International callers: 1-646-357-8785
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has completed its previously announced registered direct offering. The company raised $15.3 million in gross proceeds through the sale of 13,939,331 shares of common stock at $1.10 per share.
The net proceeds, after deducting approximately $0.8 million in placement agent fees and other offering expenses, will be used for working capital and general corporate purposes. Canaccord Genuity served as the sole placement agent for the offering.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has announced a registered direct offering of 13,939,331 shares of common stock at $1.10 per share. The offering is expected to generate $15.3 million in gross proceeds, with approximately $0.8 million in placement agent fees and other expenses.
The offering, managed by sole placement agent Canaccord Genuity, is anticipated to close around March 5, 2025. The company plans to utilize the net proceeds for working capital and general corporate purposes. The securities are being offered through a previously declared effective Form S-3 registration statement.
Lucid Diagnostics (Nasdaq: LUCD) announced that a consortium of academic medical centers has received an $8 million NIH R01 grant for a five-year clinical study of its EsoCheck® and EsoGuard® technologies. The study will evaluate esophageal precancer detection in at-risk individuals without GERD symptoms.
The research, led by investigators from Case Western Reserve University and University Hospitals, will involve 800 patients across five research centers. The study aims to improve Barrett's Esophagus (BE) detection in non-GERD at-risk populations, who account for nearly half of esophageal cancer cases but are currently excluded from screening guidelines.
The study could potentially expand EsoGuard's target population for esophageal precancer testing. The technology was originally developed at CWRU and UH, with Lucid licensing the technologies exclusively in 2018.
Lucid Diagnostics (Nasdaq: LUCD) has successfully regained compliance with Nasdaq's minimum bid price requirement, the company announced on February 25, 2025. The commercial-stage cancer prevention medical diagnostics company, a subsidiary of PAVmed Inc. (Nasdaq: PAVM), had previously been notified of non-compliance for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
To resolve this issue, Lucid was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days, a condition that was satisfied on February 21, 2025. Following this achievement, the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "LUCD".
PAVmed (PAVM) and its subsidiary Veris Health have completed a $2.37 million private placement financing. The deal includes PAVmed securities priced at-the-market and Veris common stock at a $35 million pre-money valuation.
This financing, combined with a recently secured $1.8 million non-dilutive two-year NIH grant, will fund the development of Veris' implantable physiological monitor. The company aims to enhance personalized cancer care through early detection of complications and reduced unplanned hospitalizations.
The financing represents a strategic milestone for Veris Health's commercial strategy, including regulatory clearance and launch of its implantable physiological monitor. Management believes the Veris pre-money valuation demonstrates strong investor confidence in the company's long-term commercial potential.
FAQ
What is the current stock price of Pavmed (PAVM)?
What is the market cap of Pavmed (PAVM)?
